ProShares UltraPro S&P500 vs Viatris Inc — how do they compare? ProShares UltraPro S&P500 trades at $141.79, while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while ProShares UltraPro S&P500 pays none, and Viatris Inc is trading nearer its 52-week high, ProShares UltraPro S&P500 nearer its low. Which is the better fit depends on your goals.
| UPRO | VTRS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $150.93 | $17.39 |
52-Week Low | $89.29 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Trailing returns across standard periods
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →